Drug Profile
SAR 501788
Alternative Names: SAR501788Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Neurological-disorders in France
- 11 Feb 2009 Phase-I clinical trials in Neurological disorders in France (unspecified route)
- 08 Mar 2007 Preclinical trials in Neurological disorders in France (unspecified route)